A single-centre experience of post-renal transplant lymphoproliferative disorder

Transplant International

Volumn 16, Issue 7, 2003, Pages 529-536

  Herzig, Karen A ^a   Juffs, Helen G ^a   Norris, Debra ^b   Brown, Allison M ^a   Gill, Devinder ^a   Hawley, Carmel M ^a   Cobcroft, Ralph ^a   Petrie, James B ^a   Marlton, Paula ^a   Thomson, Damien ^a   Campbell, Scott B ^a   Nicol, David L ^a   Johnson, David W ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MATER HOSPITAL   (Australia)

Author keywords

Epstein Barr virus; OKT3; Organ transplantation; Post transplant malignancy; Renal transplantation

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; DILTIAZEM; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; CHEMOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GRAFT REJECTION; HISTOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN SITU HYBRIDIZATION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL;

HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 10744219749     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2003.tb00343.x     Document Type: Article

References (49)

1. Anonymous (1993) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994
2. Baiocchi RA, Caligiuri MA (1994) Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes. Proc Natl Acad Sci U S A 91:5577-5581
3. Batiuk TD, Barry JM, Bennett WM, Meyer MM, Tolzman D, Norman DJ (1993) Incidence and type of cancer following the use of OKT3: a single center experience with 557 organ transplants. Transplant Proc 25:1391
4. Blanche S, Le Deist F, Veber F, Lenoir G, Fischer AM, Brochier J, Boucheix C, Delaage M, Griscelli C, Fischer A (1988) Treatment of severe Epstein-Barr virusinduced polyclonal B-lymphocyte proliferation by anti-B-cell monoclonal antibodies. Two cases after HLA-mismatched bone marrow transplantation. Ann Intern Med 108:199-203
5. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31:1860-1861
6. Cleary ML, Nalesnik MA, Shearer WT, Sklar J (1988) Clonal analysis of transplant-associated lymphoproliferations based on the structure of the genomic termini of the Epstein-Barr virus. Blood 72:349-352
7. Cohen JI (1991) Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine (Baltimore) 70:137-160
8. Fischer A, Blanche S, Le Bidois J, Bordigoni P, Garnier JL, Niaudet P, Morinet F, Le Deist F, Fischer AM, Griscelli C, et al. (1991) Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 324:1451-1456
9. Frizzera G, Hanto DW, Gajl Peczalska KJ, Rosai J, McKenna RW, Sibley RK, Holahan KP, Lindquist LL (1981) Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 41:4262-4279
10. Gruber SA, Skjei KL, Sothern RB, Robison L, Tzardis P, Moss A, Gillingham K, Canafax DM, Matas AJ, Dunn DL (1991) Cancer development in renal allograft recipients treated with conventional and cyclosporine immunosuppression. Transplant Proc 23:1104-1105
11. Hanto DW, Frizzera G, Gajl Peczalska J, Purtilo DT, Klein G, Simmons RL, Najarian JS (1981) The Epstein-Barr virus (EBV) in the pathogenesis of posttransplant lymphoma. Transplant Proc 13:756-760
12. Hanto DW, Frizzera G, Purtilo DT, Sakamoto K, Sullivan JL, Saemundsen AK, Klein G, Simmons RL, Najarian JS (1981) Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of the Epstein-Barr virus. Cancer Res 41:4253-4261
13. Hanto DW, Frizzera G, Gajl Peczalska KJ, Sakamoto K, Purtilo DT, Balfour HH, Jr, Simmons RL, Najarian JS (1982) Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 306:913-918
14. Hanto DW, Gajl Peczalska KJ, Frizzera G, Arthur DC, Balfour HH Jr, McClain K, Simmons RL, Najarian JS (1983) Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy. Ann Surg 198:356-369
15. Hanto DW, Frizzera G, Gajl Peczalska KJ, Simmons RL (1985) Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 39:461-472
16. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (2000) The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 13:193-207
17. Ho M, Jaffe R, Miller G, Breinig MK, Dummer JS, Makowka L, Atchison RW, Karrer F, Nalesnik MA, Starzl TE (1988) The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 45:719-727
18. Hoelzer D, Thiel E, Loffler H, Bodenstein H, Plaumann L, Buchner T, Urbanitz D, Koch P, Heimpel H, Engelhardt R (1984) Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood 64:38-47
19. Hummel M, Anagnostopoulos I, Dallenbach F, Korbjuhn P, Dimmler C, Stein H (1992) EBV infection patterns in Hodgkin's disease and normal lymphoid tissue: expression and cellular localization of EBV gene products. Br J Haematol 82:689-694
20. Khatri VP, Baiocchi RA, Bernstein ZP, Caligiuri MA (1997) Immunotherapy with low-dose interleukin-2: rationale for prevention of immune-deficiencyassociated cancer. Cancer J Sci Am 3 [Suppl 1]:S129-136
21. Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, Hagemeister F, Samuels B, Rodriguez A, Giralt S, Younes A, Przepiorka D, Claxton D, Cabanillas F, Champlin R (1998) Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16:3803-3809
22. Leblond V, Sutton L, Dorent R, Davi F, Bitker MO, Gabarre J, Charlotte F, Ghoussoub JJ, Fourcade C, Fischer A, et al. (1995) Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 13:961-968
23. Leblond V, Davi F, Charlotte F, Dorent R, Bitker MO, Sutton L, Gandjbakhch I, Binet JL, Raphael M (1998) Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 16:2052-2059
24. List AF, Greco FA, Vogler LB (1987) Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Barr virus. J Clin Oncol 5:1673-1689
25. Mathur A, Kamat DM, Filipovich AH, Steinbuch M, Shapiro RS (1994) Immunoregulatory abnormalities in patients with Epstein-Barr virus-associated B cell lymphoproliferative disorders. Transplantation 57:1042-1045
26. McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, Lane M, Gamble JF, Jones SE, Grozea PN, Gutterman J, Coltman C, Moon TE (1976) hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38:1484-1493
27. Mihalov ML, Gattuso P, Abraham K, Holmes EW, Reddy V (1996) Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center. Clin Transplant 10:248-255
28. Morrison VA, Dunn DL, Manivel JC, Gajl Peczalska KJ, Peterson BA (1994) Clinical characteristics of post-transplant lymphoproliferative disorders, Am J Med 97:14-24
29. Nalesnik MA, Rao AS, Furukawa H, Pham S, Zeevi A, Fung JJ, Klein G, Gritsch HA, Elder E, Whiteside TL, Starzl TE (1997) Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation 63:1200-1205
30. Nalesnik MA, Jaffe R, Starzl TE, Demetris AJ, Porter K, Burnham JA, Makowka L, Ho M, Locker J (1988) The pathology of posttransplant lymphoproliferative disorders occurring in the setting of Cyclosporin A prednisone immunosuppression. Am J Pathol 133:173-192
31. O'Brien S, Bernert RA, Logan JL, Lien YH (1997) Remission of posttransplant lymphoproliferative disorder after interferon alfa therapy. J Am Soc Nephrol 8:1483-1489
32. Opelz G (1996) Are post-transplant lymphomas inevitable? Nephrol Dial Transplant 11:1952-1955
33. Opelz G, Henderson R (1993) Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 342:1514-1516
34. Paiva A, Freitas L, Pratas J, Gomes H, Mota A, Marques A, Furtado AL (1998) Post-transplant lymphoproliferative disease. Nephrol Dial Transplant 13:2968-2971
35. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro Malaspina H, Childs BH, Gillio AP, Small TN, et al. (1994) Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 330:1185-1191
36. Pedagogos E, Dowling J, Rockman S, Nicholls K, Fraser I, Walker R (1996) Lymphoproliferative disorder post renal transplantation: recent experience at a single centre. Nephrology 2:133-141
37. Penn I (1988) Tumors of the immunocompromised patient. Annu Rev Med 39:63-73
38. Penn I (1990) Cancers complicating organ. N Engl J Med 323:1767-1769
39. Penn I, Brunson ME (1988) Cancers after cyclosporine therapy. Transplant Proc 20:885-892
40. Seiden MV, Sklar J (1993) Molecular genetic analysis of post-transplant lymphoproliferative disorders. Hematol Oncol Clin North Am 7:447-465
41. Shapiro RS, Chauvenet A, McGuire W, Pearson A, Craft AW, McGlave P, Filipovich A (1988) Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin. N Engl J Med 318:1334
42. Shapiro RS, McClain K, Frizzera G, Gajl Peczalska KJ, Kersey JH, Blazar BR, Arthur DC, Patton DF, Greenberg JS, Burke B (1988) Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 71:1234-1243
43. Smith JL, Wilkinson AH, Hunsicker LG, Tobacman J, Kapelanski DP, Johnson M, Wright FH, Behrendt DM, Corry RJ (1989) Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplant Proc 21:3199-3200
44. Starzl TE, Nalesnik MA, Porter KA, Ho M, lwatsuki S, Griffith BP, Rosenthal JT, Hakala TR, Shaw BW Jr, Hardesty RL (1984) Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporinesteroid therapy. Lancet 1:583-587
45. Sullivan JL, Byron KS, Brewster FE, Sakamoto K, Shaw JE, Pagano JS (1982) Treatment of life-threatening Epstein-Barr virus infection with acyclovir. Am J Med 73:262-266
46. Swinnen LJ (2000) Diagnosis and treatment of transplant-related lymphoma. Ann Oncol 11 [Suppl 1]:45-48
47. Swinnen LJ, Costanzo Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, Dizikes GJ, Pifarre R, Fisher RI (1990) Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients (comments). N Engl J Med 323:1723-1728
48. Wilkinson AH, Smith JL, Hunsicker LG, Tobacman J, Kapelanski DP, Johnson M, Wright FH, Behrendt DM, Corry RJ (1989) Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation 47:293-296
49. World Health Organization (1979) WHO handbook for reporting results of cancer treatment. WHO, Geneva